ABCAM
PBT £46.1m Dividends 8.21p
Abcam has been referred to as the ‘Apple of antibodies’. It makes and sells antibodies used in medical research, some of them derived from rabbits.
These are must-have products and the company reckons to be able to increase its share of a market that is growing by 3 to 4 per cent a year. It is targeting development of 15 to 20 per cent in its rabbit-derived product and 25 to 30 per cent for its non-primary antibodies, the two fastest-growing sectors, having achieved 24 per cent and 28 per cent, respectively, in the year to June 30.
At constant rates, revenues for its core products were up by almost 17 per cent to £135.4 million over the year. This